BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37866002)

  • 1. Antigen cross-presentation in dendric cells: From bench to bedside.
    Zhang T; Aipire A; Li Y; Guo C; Li J
    Biomed Pharmacother; 2023 Dec; 168():115758. PubMed ID: 37866002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-presentation of exogenous antigens on MHC I molecules.
    Colbert JD; Cruz FM; Rock KL
    Curr Opin Immunol; 2020 Jun; 64():1-8. PubMed ID: 31927332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells.
    Montealegre S; van Endert PM
    Front Immunol; 2018; 9():3098. PubMed ID: 30666258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathways of MHC I cross-presentation of exogenous antigens.
    Cruz FM; Chan A; Rock KL
    Semin Immunol; 2023 Mar; 66():101729. PubMed ID: 36804685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-presentation of Exogenous Antigens.
    Li B; Hu L
    Transfus Clin Biol; 2019 Nov; 26(4):346-351. PubMed ID: 30797678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
    Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
    Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy.
    Moussion C; Delamarre L
    Semin Immunol; 2024 Feb; 71():101848. PubMed ID: 38035643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation.
    Cohn L; Chatterjee B; Esselborn F; Smed-Sörensen A; Nakamura N; Chalouni C; Lee BC; Vandlen R; Keler T; Lauer P; Brockstedt D; Mellman I; Delamarre L
    J Exp Med; 2013 May; 210(5):1049-63. PubMed ID: 23569326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.
    Steinman RM
    Mt Sinai J Med; 2001 May; 68(3):160-6. PubMed ID: 11373688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lectin Siglec-G inhibits dendritic cell cross-presentation by impairing MHC class I-peptide complex formation.
    Ding Y; Guo Z; Liu Y; Li X; Zhang Q; Xu X; Gu Y; Zhang Y; Zhao D; Cao X
    Nat Immunol; 2016 Oct; 17(10):1167-75. PubMed ID: 27548433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
    Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
    Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I.
    Horrevorts SK; Duinkerken S; Bloem K; Secades P; Kalay H; Musters RJ; van Vliet SJ; García-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():1231. PubMed ID: 29963041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications.
    Wilson NS; Villadangos JA
    Adv Immunol; 2005; 86():241-305. PubMed ID: 15705424
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Del Balzo D; Capmany A; Cebrian I; Damiani MT
    Front Immunol; 2021; 12():662096. PubMed ID: 33936099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CD74-dependent MHC class I endolysosomal cross-presentation pathway.
    Basha G; Omilusik K; Chavez-Steenbock A; Reinicke AT; Lack N; Choi KB; Jefferies WA
    Nat Immunol; 2012 Feb; 13(3):237-45. PubMed ID: 22306692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.
    Ho NI; Camps MGM; de Haas EFE; Ossendorp F
    Eur J Immunol; 2018 Jul; 48(7):1164-1173. PubMed ID: 29676785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The show and tell of cross-presentation.
    Blander JM; Yee Mon KJ; Jha A; Roycroft D
    Adv Immunol; 2023; 159():33-114. PubMed ID: 37996207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential use of autophagy by primary dendritic cells specialized in cross-presentation.
    Mintern JD; Macri C; Chin WJ; Panozza SE; Segura E; Patterson NL; Zeller P; Bourges D; Bedoui S; McMillan PJ; Idris A; Nowell CJ; Brown A; Radford KJ; Johnston AP; Villadangos JA
    Autophagy; 2015; 11(6):906-17. PubMed ID: 25950899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-presentation by dendritic cells.
    Joffre OP; Segura E; Savina A; Amigorena S
    Nat Rev Immunol; 2012 Jul; 12(8):557-69. PubMed ID: 22790179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.